We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
+26.51%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$2.28B
AUM Growth
+$663M
(+41%)
Cap. Flow
+$192M
Cap. Flow
% of AUM
8.42%
Top 10 Holdings %
Top 10 Hldgs %
37.08%
Holding
98
New
19
Increased
31
Reduced
23
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$56.8M |
| 2 |
Biogen
BIIB
|
+$47.5M |
| 3 |
UnitedHealth
UNH
|
+$32.1M |
| 4 |
Lantheus
LNTH
|
+$30.4M |
| 5 |
AutoZone
AZO
|
+$29.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VXRT
Vaxart
VXRT
|
+$72M |
| 2 |
Deckers Outdoor
DECK
|
+$30.5M |
| 3 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$29.6M |
| 4 |
Amazon
AMZN
|
+$25.4M |
| 5 |
Dollar Tree
DLTR
|
+$22.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 45.31% |
| 2 | Consumer Discretionary | 15.79% |
| 3 | Consumer Staples | 9.9% |
| 4 | Technology | 5.31% |
| 5 | Industrials | 3.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
| $200M | 8.79% |
6,500
+500
| +8% | +$146K |
|
2
PUT
iShares Russell 2000 ETF
IWM
$80.9B
| $172M | 7.54% |
12,000
+5,000
| +71% | +$656K |
|
3
Avalo Therapeutics
AVTX
$976M
| $77.8M | 3.41% |
10,387
+609
| +6% | +$4.42M |
|
|
4
UnitedHealth
UNH
$382B
| $59M | 2.59% |
200,000
+112,000
| +127% | +$32.1M |
|
5
Bristol-Myers Squibb
BMY
$127B
| $58.8M | 2.58% |
1,000,000
+352,000
| +54% | +$21.1M |
|
|
6
Biogen
BIIB
$29.9B
| $57.8M | 2.53% |
216,000
+158,000
| +272% | +$47.5M |
|
|
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
| $56.1M | 2.46% |
500,000
+72,000
| +17% | +$7.64M |
|
8
Vanda Pharmaceuticals
VNDA
$312M
| $54.9M | 2.41% |
4,800,000
+232,000
| +5% | +$2.63M |
|
9
Energizer
ENR
$1.44B
| $54.5M | 2.39% |
1,148,000
+276,000
| +32% | +$11.3M |
|
|
10
Medtronic
MDT
$107B
| $54.3M | 2.38% |
+592,000
| New | +$56.8M |
|
11
Supernus Pharmaceuticals
SUPN
$2.68B
| $52.4M | 2.3% |
2,208,000
-792,000
| -26% | -$17.5M |
|
|
12
Lantheus
LNTH
$6.82B
| $51.8M | 2.27% |
3,624,000
+2,300,000
| +174% | +$30.4M |
|
13
Incyte
INCY
$23.5B
| $45.3M | 1.99% |
436,000
-92,000
| -17% | -$8.87M |
|
14
Central Garden & Pet Co Class A
CENTA
$2.41B
| $44.7M | 1.96% |
1,655,000
-220,000
| -12% | -$5.52M |
|
15
Regeneron Pharmaceuticals
REGN
$68.8B
| $42.4M | 1.86% |
68,000
+4,000
| +6% | +$2.27M |
|
16
Five Below
FIVE
$11.2B
| $40.4M | 1.77% |
378,005
+43,411
| +13% | +$4.07M |
|
|
BHVN
17
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $36.6M | 1.6% |
500,000
-556,000
| -53% | -$29.6M |
|
18
Dropbox
DBX
$6.81B
| $35.4M | 1.55% |
1,624,000
-68,000
| -4% | -$1.44M |
|
19
Dollar General
DG
$25.9B
| $35.3M | 1.55% |
185,421
+19,788
| +12% | +$3.58M |
|
20
Ross Stores
ROST
$76.6B
| $34.9M | 1.53% |
409,344
+291,630
| +248% | +$26.4M |
|
|
BLUE
21
DELISTED
bluebird bio
BLUE
| $34.7M | 1.52% |
43,850
-6,176
| -12% | -$4.66M |
|
|
22
Amazon
AMZN
$2.5T
| $34.5M | 1.51% |
250,000
-210,000
| -46% | -$25.4M |
|
23
AptarGroup
ATR
$8.45B
| $32.3M | 1.41% |
288,000
+138,000
| +92% | +$14.7M |
|
|
24
AutoZone
AZO
$48.3B
| $31.6M | 1.39% |
+28,000
| New | +$29.5M |
|
|
AMAG
25
DELISTED
AMAG Pharmaceuticals
AMAG
| $31.5M | 1.38% |
4,120,000
| – | – |
|
Similar funds
CRC
RMDI
F
DWM
DCP
EW
AIM
O
Armistice Capital's Q2 2020 Portfolio in Review
As of Q2 2020, Armistice Capital held 98 positions worth $2.28B, up 41% from $1.62B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Armistice Capital deployed $192M of net new capital in Q2 2020, opening 19 new positions and adding to 31 existing holdings. Its largest new stake was Medtronic: 592,000 shares worth $54.3M.
By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 47% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
On the sell side, the largest reduction was Vaxart, an estimated $72M trimmed.
- Armistice Capital's largest Q2 2020 buy was Medtronic: 592,000 shares worth $54.3M.
- Armistice Capital added most to Biogen in Q2 2020, an estimated $47.5M increase.
- Armistice Capital's biggest Q2 2020 reduction was Vaxart, cutting an estimated $72M.
- Armistice Capital fully exited Deckers Outdoor in Q2 2020, selling an estimated $30.5M.
- Armistice Capital's ten largest holdings make up 37% of its $2.28B portfolio in Q2 2020.
- Armistice Capital opened 19 new positions and closed 19 in Q2 2020.
- Armistice Capital's portfolio value rose 41% quarter-over-quarter to $2.28B.
Based on Armistice Capital's 13F filing for Q2 2020, filed 14 Aug 2020.